New strategy aims to stop deadly skin cancer from coming back
NCT ID NCT07178457
Summary
This study tests if giving the drug brentuximab vedotin as a preventive treatment after a stem cell transplant can stop an aggressive type of skin cancer (CTCL) from returning. It will involve 84 adults whose cancer had responded to prior treatments but is at high risk of relapse. Patients will receive either the drug or a placebo to see if early, preventive treatment improves survival without the cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.